Jennifer Gillman1, Jennifer Chun2, Shira Schwartz2, Freya Schnabel2, Linda Moy3. 1. Department of Radiology, New York University School of Medicine, Perlmutter Cancer Center, 160 East 34th Street, New York, NY, 10016, USA. 2. Department of Surgery, New York University School of Medicine, Perlmutter Cancer Center, 160 East 34th Street, New York, NY, 10016, USA. 3. Department of Radiology, New York University School of Medicine, Perlmutter Cancer Center, 160 East 34th Street, New York, NY, 10016, USA. Electronic address: Linda.Moy@nyumc.org.
Abstract
PURPOSE: The purpose was to evaluate the relationship between body mass index (BMI), mammographic breast density, magnetic resonance (MR) background parenchymal enhancement (BPE), and MR fibroglandular tissue (FGT) in women with breast cancer. METHODS: Our institutional database was queried for patients with preoperative mammography and breast MR imaging. RESULTS: There were 573 women eligible for analysis. Elevated BMI was associated with advanced stage of disease (P=.01), lower mammographic density (P<.0001), lower FGT (P<.0001), higher BPE (P=.005), and nonpalpable lesions (P=.04). CONCLUSIONS: Higher BMI was associated with decreased breast density and FGT. Higher BMI was also associated with advanced stage disease and nonpalpable tumors on clinical exam.
PURPOSE: The purpose was to evaluate the relationship between body mass index (BMI), mammographic breast density, magnetic resonance (MR) background parenchymal enhancement (BPE), and MR fibroglandular tissue (FGT) in women with breast cancer. METHODS: Our institutional database was queried for patients with preoperative mammography and breast MR imaging. RESULTS: There were 573 women eligible for analysis. Elevated BMI was associated with advanced stage of disease (P=.01), lower mammographic density (P<.0001), lower FGT (P<.0001), higher BPE (P=.005), and nonpalpable lesions (P=.04). CONCLUSIONS: Higher BMI was associated with decreased breast density and FGT. Higher BMI was also associated with advanced stage disease and nonpalpable tumors on clinical exam.
Authors: Siun M Walsh; Sandra B Brennan; Emily C Zabor; Laura H Rosenberger; Michelle Stempel; Lizza Lebron-Zapata; Mary L Gemignani Journal: Ann Surg Oncol Date: 2019-08-08 Impact factor: 5.344
Authors: Annie Tang; Caitlin M Cohan; Keith S Hansen; Genna Beattie; Heather I Greenwood; Rita A Mukhtar Journal: Breast Cancer Res Treat Date: 2021-03-27 Impact factor: 4.872
Authors: Andrea Brown; Elizabeth J Buss; Christine Chin; Gaotong Liu; Shing Lee; Roshni Rao; Brett Taback; Lisa Wiechmann; David Horowitz; Julie C Choi; Leah M Katz; Eileen P Connolly Journal: Front Oncol Date: 2022-06-29 Impact factor: 5.738
Authors: Dianning He; Devkumar Mustafi; Xiaobing Fan; Sully Fernandez; Erica Markiewicz; Marta Zamora; Jeffrey Mueller; Joseph R Sachleben; Matthew J Brady; Suzanne D Conzen; Gregory S Karczmar Journal: PLoS One Date: 2018-01-11 Impact factor: 3.240
Authors: Jennifer D Brooks; Rebecca A G Christensen; Janice S Sung; Malcolm C Pike; Irene Orlow; Jonine L Bernstein; Elizabeth A Morris Journal: NPJ Breast Cancer Date: 2022-08-25
Authors: Roxanna Hellgren; Ariel Saracco; Fredrik Strand; Mikael Eriksson; Ann Sundbom; Per Hall; Paul W Dickman Journal: Acta Radiol Date: 2020-03-26 Impact factor: 1.990
Authors: Braden Miller; Hunter Chalfant; Alexandra Thomas; Elizabeth Wellberg; Christina Henson; Molly W McNally; William E Grizzle; Ajay Jain; Lacey R McNally Journal: Int J Mol Sci Date: 2021-03-09 Impact factor: 5.923